Skip to Main Content
Table 2—

Inflammatory markers

Orlistat + intervention
Placebo + intervention
BaselineYear 1BaselineYear 1
n 17
 
 21
 
 
IL-6 (pg/ml) 2.13 (1.56–2.88) 1.48 (1.18–2.04)* 2.44 (1.62–3.20) 1.37 (0.96–2.43)* 
TNF-α (pg/ml) 3.68 ± 1.00 2.64 ± 0.71 3.90 ± 1.22 3.05 ± 0.93* 
C-reactive protein (mg/l) 2.84 (1.16–6.28) 2.03 (1.00–3.46) 3.16 (1.43–5.50) 1.97 (0.75–4.63)* 
PAI-1 (ng/ml) 51.4 (36.0–87.0) 24.0 (10.4–33.2)* 78.6 (46.4–113.3) 54.0 (22.6–80.2) 
Fibrinogen (mg/dl) 247.5 ± 64.3 342.6 ± 62.2 254.7 ± 104.7 332.0 ± 74.2* 
Orlistat + intervention
Placebo + intervention
BaselineYear 1BaselineYear 1
n 17
 
 21
 
 
IL-6 (pg/ml) 2.13 (1.56–2.88) 1.48 (1.18–2.04)* 2.44 (1.62–3.20) 1.37 (0.96–2.43)* 
TNF-α (pg/ml) 3.68 ± 1.00 2.64 ± 0.71 3.90 ± 1.22 3.05 ± 0.93* 
C-reactive protein (mg/l) 2.84 (1.16–6.28) 2.03 (1.00–3.46) 3.16 (1.43–5.50) 1.97 (0.75–4.63)* 
PAI-1 (ng/ml) 51.4 (36.0–87.0) 24.0 (10.4–33.2)* 78.6 (46.4–113.3) 54.0 (22.6–80.2) 
Fibrinogen (mg/dl) 247.5 ± 64.3 342.6 ± 62.2 254.7 ± 104.7 332.0 ± 74.2* 

Data are means ± SD or median (interquartile range 25th–75th percentile).

*

P < 0.05,

P < 0.001 year 1 vs. baseline;

P < 0.05 placebo vs. orlistat.

Close Modal

or Create an Account

Close Modal
Close Modal